Free shipping on all orders over $ 500

Brivanib alaninate

Cat. No. M1687
Brivanib alaninate Structure
Synonym:

BMS-582664

Size Price Availability Quantity
10mM*1mL in DMSO USD 130  USD130 In stock
5mg USD 117  USD117 In stock
10mg USD 197  USD197 In stock
50mg USD 700  USD700 In stock
100mg USD 1200  USD1200 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Brivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development for the treatment of hepatocellular and colon carcinomas. In vitro and in vivo studies were conducted to characterize the preclinical pharmacokinetics and disposition of brivanib and brivanib alaninate, and antitumor efficacy in mice bearing human xenografts.

Chemical Information
Molecular Weight 441.46
Formula C22H24FN5O4
CAS Number 649735-63-7
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Narang et al. J Pharm Pharmacol. Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs.

[2] Zhao et al. J Pharm Sci. Acid-catalyzed hydrolysis of BMS-582664: Degradation product identification and mechanism elucidation.

[3] Garrett et al. Br J Cancer. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.

Related VEGFR/PDGFR Products
Isolinderalactone

Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through the inhibition of VEGFR2 activation in endothelial cells. Isolinderalactone suppressed the expression of B-cell lymphoma 2 (BCL-2), as well as of survivin and X-linked inhibitor of apoptosis protein (XIAP).

Oglufanide

Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus.

KLTWQELYQLKYKGI

KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF.

Protein LMWP

Protein LMWP is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity.

CBO-P11

CBO-P11 specifically binds to receptor of VEGFR-2 and is used as targeting ligand for tumor angiogenesis.

  Catalog
Abmole Inhibitor Catalog




Keywords: Brivanib alaninate, BMS-582664 supplier, VEGFR/PDGFR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.